Recent News

• 03.25.2025 - iAccess Alpha Virtual Best Ideas Spring Conference 2025
• 03.24.2025 - Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
• 03.18.2025 - Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting
• 03.17.2025 - Protalix BioTherapeutics Fiscal Year 2024 Financial and Business Results Conference Call
• 03.17.2025 - Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results
• 03.10.2025 - Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025
• 02.06.2025 - Dror Bashan Interview
• 02.04.2025 - Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
• 02.04.2025 - Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
• 12.23.2024 - Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Recent Filings

• 03.17.2025 - 8-K Current report
• 03.17.2025 - EX-99.1 EX-99.1
• 03.17.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.17.2025 - 8-K Current report
• 12.31.2024 - 8-K Current report
• 12.23.2024 - EX-99.1 EX-99.1
• 12.23.2024 - 8-K Current report